Sistema de Salut de Catalunya
Institut Català de la Salut
[Kroese TE] Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [Bronzwaer S] Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [van Rossum PSN] Department of Radiation Oncology, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands. [Schoppman SF] Department of Surgery, Medical University of Vienna, Vienna University, Vienna, Austria. [Deseyne PRAJ] Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. [van Cutsem E] Department of Medical Oncology, KU Leuven, Leuven University, Leuven, Belgium. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. CIBERONC, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-05-07T08:31:17Z
2024-05-07T08:31:17Z
2024-04-16
Esophageal cancer; Gastric cancer; Oligometastasis
Càncer d'esòfag; Càncer gàstric; Oligometàstasi
Cáncer de esófago; Cáncer gástrico; Oligometástasis
Introduction The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. Results Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ≤ 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI ≤ 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. Discussion These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
Article
Published version
English
Decisió de grup; Esòfag - Càncer - Tractament; Estómac - Càncer - Tractament; Radioteràpia; Cirurgia; INFORMATION SCIENCE::Information Science::Systems Analysis::Delphi Technique; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Metastasectomy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Radiotherapy; CIENCIA DE LA INFORMACIÓN::Ciencias de la información::análisis de sistemas::técnica Delfos; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias gástricas; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::metastasectomía; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::radioterapia
Elsevier
European Journal of Cancer;204
https://doi.org/10.1016/j.ejca.2024.114062
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3436]
